New long-acting injectable compositions comprising finasteride for the prevention or treatment of androgenetic alopecia
By developing a long-acting subcutaneous injection composition of finasteride, the problem of daily administration of oral finasteride preparations has been solved, achieving continuous inhibition of type II 5α-reductase for more than one month, thus improving the stability and efficacy of treating androgenetic alopecia.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- INVENTAGE LAB INC
- Filing Date
- 2024-12-19
- Publication Date
- 2026-07-14
AI Technical Summary
Existing oral finasteride formulations require daily administration and cannot sustain the inhibition of type II 5α-reductase for more than one month, leading to recurring symptoms of androgenetic alopecia. Furthermore, the drug has a short half-life, resulting in unstable treatment efficacy.
Develop a long-acting subcutaneous injection composition containing finasteride, which can inhibit type II 5α-reductase for more than one month with a single injection, increase the in vivo half-life of finasteride to 100-160 hours, and be administered subcutaneously using a microparticle LAI formulation, comprising a uniformly mixed microsphere of biodegradable polymer and finasteride.
It achieves sustained release of finasteride in the body for more than one month, inhibits the conversion of testosterone to DHT, improves the stability and predictability of the treatment of androgenetic alopecia, and enhances the uniformity of treatment effects.
Smart Images
Figure CN122396481A_ABST